Last reviewed · How we verify
PEP02
At a glance
| Generic name | PEP02 |
|---|---|
| Also known as | liposome irinotecan, liposomal irinotecan, Liposome irinotecan |
| Sponsor | PharmaEngine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (PHASE2)
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (PHASE3)
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial (PHASE2)
- Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients (PHASE2)
- Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors (PHASE1)
- Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin (PHASE2)
- TAS102 in Combination With NAL-IRI in Advanced GI Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEP02 CI brief — competitive landscape report
- PEP02 updates RSS · CI watch RSS
- PharmaEngine portfolio CI